Human B cells that hyperexpress a triad of costimulatory molecules via avipox-vector infection: An alternative source of efficient antigen-presenting cells

Blood

Volumn 104, Issue 1, 2004, Pages 192-199

  Palena, Claudia ^a   Zhu, MingZhu ^a   Schlom, Jeffrey ^a   Tsang, Kwong Yok ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CD40 LIGAND; CD8 ANTIGEN; EPITOPE; HLA A2 ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; MUCIN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 4; VIRUS PROTEIN;

ADOPTIVE TRANSFER; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FOWLPOX VIRUS; HUMAN; HUMAN CELL; IMMUNOTHERAPY; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; VIRUS RECOMBINANT;

EID: 3042751493     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-09-3211     Document Type: Article

References (37)

1. Rock KL, Rothstein L, Gamble S, Fleischacker C. Characterization of antigen-presenting cells that present exogenous antigens in association with class I MHC molecules. J Immunol. 1993;150:438-446.
2. Ke Y, Kapp JA. Exogenous antigens gain access to the major histocompatibility complex class I processing pathway in B cells by receptor-mediated uptake. J Exp Med. 1996;184:1179-1184.
3. Vidard L, Kovacsovics-Bankowski M, Kraeft SK, Chen LB, Benacerraf B, Rock KL. Analysis of MHC class II presentation of particulate antigens of B lymphocytes. J Immunol. 1996;156:2809-2818.
4. + T cells to protein antigens in vivo. J Immunol. 1995;155:3734-3741.
5. Cella M, Sallusto F, Lanzavecchia A. Origin, maturation and antigen presentation function of dendritic cells. Curr Opin Immunol. 1997;9:10-16.
6. Croft M, Bradley LM, Swain SL. Naive versus memory CD4 T cell response to antigen: memory cells are less dependent on accessory cell costimulation and can respond to many antigen-presenting cell types including resting B cells. J Immunol. 1994;152:2675-2685.
7. Evans DE, Munks MW, Purkerson JM, Parker DC. Resting B lymphocytes as APC for naive T lymphocytes: dependence on CD40 ligand/CD40. J Immunol. 2000;164:688-697.
8. Krieger JI, Grammer SF, Grey HM, Chesnut RW. Antigen presentation by splenic B cells: resting B cells are ineffective, whereas activated B cells are effective accessory cells for T cell responses. J Immunol. 1985;135:2937-2945.
9. Reid CD. Dendritic cells and immunotherapy for malignant disease. Br J Haematol. 2001;112:874-887.
10. Romani N, Reider D, Heuer M, et al. Generation of mature dendritic cells from human blood: an improved method with special regard to clinical applicability. J Immunol Methods. 1996;196:137-151.
11. Morse M, Zhou LJ, Tedder TF, Lyerly HK, Smith C. Generation of dendritic cells in vitro from peripheral blood mononuclear cells with granulocyte- macrophage colony-stimulating factor, interleukin-4, and tumor necrosis factor-α for use in cancer immunotherapy. Ann Surg. 1997;226:6-16.
12. Mueller DL, Jenkins MK, Schwartz RH. Clonal expansion versus functional clonal inactivation: a costimulatory signaling pathway determines the outcome of T-cell antigen receptor occupancy. Annu Rev Immunol. 1989;7:445-480.
13. Liu Y, Lindsey PS. Costimulation of T-cell growth. Curr Opin Immunol. 1992;4:265-270.
14. Tsang K, Zhu MZ, Even J, Gulley J, Arlen P, Schlom J. The infection of human dendritic cells with recombinant avipox vectors expressing a costimulatory molecule transgene (CD80) to enhance the activation of antigen-specific cytolytic T cells. Cancer Res. 2001;61:7568-7576.
15. Zhu MZ, Terasawa H, Gulley J, et al. Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells. Cancer Res. 2001;61:3725-3734.
16. Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM, Schlom J. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst. 1995;87:982-990.
17. Tsang KY, Zhu M, Nieroda CA, et al. Phenotypic stability of a cytotoxic T-cell line directed against an immunodominant epitope of human carcinoembryonic antigen. Clin Cancer Res. 1997;3:2439-2449.
18. Tsang KY, Palena C, Gulley J, Arlen P, Schlom J. A human cytotoxic T-lymphocyte epitope and its agonist epitope from the nonvariable number of tandem repeat sequence of MUC-1. Clin Cancer Res. 2004;10:2139-2149.
19. Zaremba S, Barzaga E, Zhu M, Soares N, Tsang KY, Schlom J. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res. 1997;57:4570-4577.
20. Falk K, Rötzschke O, Stevanovic S, Jung G, Rammensee HG. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature. 1991;351:290-296.
21. Evans C, Bauer S, Grubert T, et al. HLA-A2-restricted peripheral blood cytolytic T lymphocytes respond to HPV type 16 proteins E6 and E7 from patients with neoplastic cervical lesions. Cancer Immunol Immunother. 1996;42:151-160.
22. Terasawa H, Tsang KY, Gulley J, Arlen P, Schlom J. Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen. Clin Cancer Res. 2002;8:41-53.
23. Perkus ME, Piccini A, Lipinskas BR, Paoletti E. Recombinant vaccinia virus: immunization against multiple pathogens. Science. 1985;229:981-984.
24. Schmitt JF, Stunnenberg HG. Sequence and transcriptional analysis of the vaccinia virus Hind III fragment. J Virol. 1988;62:1889-1897.
25. Chakrabarti S, Sisler JR, Moss B. Compact, synthetic vaccinia virus early/late promoter for protein expression. Biotechniques. 1999;23:1094-1097.
26. Gritz L, Destree A, Cormier N, et al. Generation of hybrid genes and proteins by vaccinia virus-mediated recombination: application to human immunodeficiency virus type 1 env. J Virol. 1990;64:5948-5957.
27. Young IT. Proof without prejudice: use of the Kolmogorov-Smirnov test for the analysis of histograms from flow systems and other sources. J Histochem Cytochem. 1977;25:935-941.
28. Schultze JL, Michalak S, Seamon MJ, et al. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest. 1997;100:2757-2765.
29. Von Bergwelt-Baildon MS, Vonderheide RH, Maecker B, et al. Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application. Blood. 2002;99:3319-3325.
30. Schluer G, Steinman RM. Dendritic cells as adjuvants for immune-mediated resistance to tumors. J Exp Med. 1997;186:1183-1187.
31. + T lymphocyte responses in vitro using dendritic cells. J Immunol. 1999;162:5197-5204.
32. Peterson AC, Harlin H, Gajewski TF. Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma. J Clin Oncol. 2003;21:2342-2348.
33. Cassell DJ, Schwartz RH. A quantitative analysis of antigen-presenting cell function: activated B cells stimulate naive CD4 T cells but are inferior to dendritic cells in providing costimulation. J Exp Med. 1994;180:1829-1840.
34. Hodge JW, Grosenbach DW, Rad AN, Giuliano M, Sabzevari H, Schlom J. Enhancing the potency of peptide-pulsed antigen presenting cells by vector-driven hyperexpression of a triad of costimulatory molecules. Vaccine. 2001;19:3552-3567.
35. Oh SK, Hodge JW, Ahlers JD, Burke DS, Schlom J, Berzofsky JA. Selective induction of high avidity CTL by altering the balance of signals from APC. J Immunol. 2003;170:2523-2530.
36. Ashwell JD, DeFranco AL, Paul WE, Schwartz RH. Can resting B cells present antigen to T cells? Fed Proc. 1985;44:2475-2479.
37. Bronte V, Carroll MW, Goletz TJ, et al. Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. Proc Natl Acad Sci U S A. 1997;94:3183-3188.